|Articles|April 9, 2023
- Pharmaceutical Executive: April 2023
- Volume 43
- Issue 4
Pharmaceutical Executive, April 2023 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2023 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 2 years ago
Unwavering Focusover 2 years ago
A Brand Game-Changer? TikTok and Pharma Marketingalmost 3 years ago
Tough—But Rewarding: The Evolution of the Chief Diversity Officeralmost 3 years ago
Does the Biotech Sector Have Reason to Be Optimistic?almost 3 years ago
Kudos and Hurdles for Industry, FDA in Tackling Rare Diseasesalmost 3 years ago
The Payer Value Deficit in Orphan Drugsalmost 3 years ago
Seizing On Asia’s Opportune Market for Novel Vaccinesalmost 3 years ago
European Policy Called Out as Threat to Drug Trade and InvestmentNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
3
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
4
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
5

